A systematic study of molecular targets of cannabidiol in Alzheimer's disease DOI Creative Commons

Nil Patil,

Kalpana S. Patil, Mukul Jain

et al.

Journal of Alzheimer s Disease Reports, Journal Year: 2024, Volume and Issue: 8(1), P. 1339 - 1360

Published: March 1, 2024

Background Alzheimer's disease (AD) is a prevalent, incurable, and chronic neurodegenerative condition characterized by the accumulation of amyloid-β protein (Aβ), disrupting various bodily systems. Despite lack cure, phenolic compounds like cannabidiol (CBD), non-psychoactive component cannabis, have emerged as potential therapeutic agents for AD. Objective This systematic review explores impact different types on AD, unveiling their neuroprotective mechanisms. Methods The research used PubMed, Scopus, Web Science databases with keywords “Alzheimer's disease” “Cannabidiol.” Studies were evaluated based title, abstract, relevance to treating AD CBD. No restrictions type or publication year. Excluded hypothesis papers, reviews, books, unavailable articles, etc. Results Microsoft Excel identified 551 92 included in study, but only 22 thoroughly evaluated. In-vivo in-silico studies indicate that CBD may disrupt Aβ 42 , reduce pro-inflammatory molecule release, prevent reactive oxygen species formation, inhibit lipid oxidation, counteract Aβ-induced increases intracellular calcium, thereby protecting neurons from apoptosis. Conclusions In summary, study indicates its analogs production . Overall, these findings support alleviating underlying pathology symptoms associated underscoring crucial need further rigorous scientific investigation elucidate applications mechanisms

Language: Английский

Cannabidiol induces ERK activation and ROS production to promote autophagy and ferroptosis in glioblastoma cells DOI
Na Young Kim,

Siddegowda Gopalapura Shivanne Gowda,

Seok‐Geun Lee

et al.

Chemico-Biological Interactions, Journal Year: 2024, Volume and Issue: 394, P. 110995 - 110995

Published: April 5, 2024

Language: Английский

Citations

13
Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease DOI Creative Commons
Jordan P. Hickey, Andrila E. Collins,

Mackayla L. Nelson

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(5), P. 4379 - 4402

Published: May 6, 2024

Alzheimer’s disease (AD) is a progressive neurodegenerative and the most common form of dementia globally. Although direct cause AD remains under debate, neuroinflammation oxidative stress are critical components in its pathogenesis progression. As result, compounds like cannabidiol (CBD) being increasingly investigated for their ability to provide antioxidant anti-inflammatory neuroprotection. CBD primary non-psychotropic phytocannabinoid derived from Cannabis sativa. It has been found beneficial outcomes variety medical conditions gaining increasing attention potential therapeutic application AD. not psychoactive lipophilic nature allows rapid distribution throughout body, including across blood–brain barrier (BBB). also possesses anti-inflammatory, antioxidant, neuroprotective properties, making it viable candidate treatment. This review outlines CBD’s mechanism action, role AD, effectiveness limitations preclinical models

Language: Английский

Citations

9
Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy DOI Creative Commons

MariaLuisa Vigano,

Lixing Wang,

Alia As’sadiq

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 5, 2025

Cannabinoids relieve pain, nausea, anorexia and anxiety, improve quality of life in several cancer patients. The immunotherapy with checkpoint inhibitors (ICIs), although very successful a subset patients, is accompanied by moderate to severe immune-related adverse events (ir-AE) that often necessitate its discontinuation. Because their role symptomatic relief, cannabinoids have been used combination immune inhibitor (ICI) immunotherapy. A few studies strongly suggest the use medicinal cannabis patients attenuates many ir-AE associated ICI increase tolerability. However, no significant beneficial effects on overall survival, progression free survival or relapses were observed; rather, some noted concurrent administration clinical benefits latter. cannabinoids' well documented immunosuppressive mediated through cannabinoid recptor-2 (CB2), we propose considering this receptor as an inhibitory per se. simultaneous neutralization CB2, treatment, may lead better outcomes receiving In regard, such cannabidiol (CBD) cannabigerol (CBG), little agonism for be therapeutic choices. Additional strategies e.g., monoacylglycerol lipase (MAGL) degrade endocannabinoids lipogenesis formation lipid bilayers cells also explored. Future should take into consideration gut microbiota, CYP450 polymorphism haplotypes, cannabinoid-drug interactions genetic somatic variations occurring receptors signaling pathways personalized cannabis-based therapies ICIs. This rational knowledge-based regimens tailored individual

Language: Английский

Citations

1
Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits DOI
Saurabh Kumar Jha, Vinod K. Nelson,

Punna Rao Suryadevara

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 100, P. 102386 - 102386

Published: July 4, 2024

Language: Английский

Citations

8
Mitochondrial signaling pathways and their role in cancer drug resistance DOI
Ashwani Sharma, Tarun Virmani, Girish Kumar

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 122, P. 111329 - 111329

Published: Aug. 5, 2024

Language: Английский

Citations

8
CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions DOI Creative Commons
Lixuan Qian, Jessica L. Beers, Klarissa D. Jackson

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(4), P. 484 - 484

Published: April 1, 2024

Cannabinoid use has surged in the past decade, with a growing interest expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, increased of CBD THC raises risk drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially populations, remain inadequately investigated. While some clinical trials have explored between therapeutic drugs like antiepileptic CBD/THC, more potential to be examined. This review summarizes published studies on THC–drug interactions, outlines mechanisms involved, discusses physiological considerations pharmacokinetics (PK) DDI populations (including pregnant lactating women, pediatrics, older adults, patients hepatic or renal impairments, others), presents modeling approaches that can describe associated The PK poorly characterized, limited investigating involving CBD/THC these Therefore, it is critical evaluate medications are commonly used Modeling aid understanding interactions.

Language: Английский

Citations

7
Research progress in the management of vascular disease with cannabidiol: a review DOI Creative Commons
Yilong Guo, Wei Ren, Jianqing Deng

et al.

Journal of Cardiothoracic Surgery, Journal Year: 2024, Volume and Issue: 19(1)

Published: Jan. 3, 2024

Abstract The morbidity and mortality rates associated with vascular disease (VD) have been gradually increasing. Currently, the most common treatment for VD is surgery, progress in drug therapy remaining slow. Cannabidiol (CBD) a natural extract of Cannabis sativa L. sedative, analgesic, nonaddictive properties. CBD binds to 56 cardiovascular-related receptors exerts extensive regulatory effects on cardiovascular system, making it potential pharmacological agent management VD. However, studies focused neurological cardiac diseases, research still rare. In this review, we summarize currently available data VD, addressing four aspects: major molecular targets management, pharmacokinetic properties, therapeutic VDs, side effects. findings indicate that has anti-anxiety, anti-oxidation, anti-inflammatory properties can inhibit abnormal proliferation apoptosis smooth muscle endothelial cells; these suggest as atherosclerosis, stress-induced hypertension, diabetes-related vasculopathy, ischemia-reperfusion injury, damage caused by smoking alcohol abuse. This study provides theoretical basis further

Language: Английский

Citations

4
Identifying the optimal dose of cannabidiol by intrabuccal administration in Kramnik (C3HeB/FeJ) mice DOI Creative Commons
Oluwadara Pelumi Omotayo,

Siyethemba Bhengu,

Kobus Venter

et al.

Animal Models and Experimental Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Abstract Background Cannabidiol (CBD) has numerous therapeutic properties, and is used to treat neurological conditions, such as neuroinflammation. However, the optimal dose of CBD penetrate brain requires further investigation. The primary aim this study was use a mouse model intrabuccal route for administration determine at which can brain. secondary whether sex confounding factor. Methods Thirty adult Kramnik mice, divided equally into three groups, were administered oil intrabuccally doses—10, 20, 30 mg/kg, euthanized 6 h later, whole brain, urine, blood samples collected. Liquid chromatography with tandem mass spectrometry analyze collected samples. Results its metabolites—7‐carboxy cannabidiol (7‐COOH‐CBD), 7‐hydroxy (7‐OH‐CBD) 6‐hydroxy (6‐OH‐CBD), identified quantified in all 10 20 mg/kg doses produced similar results but group given had least variation. yielded highest abundance metabolites samples, also greatest Sex only became factor mg/kg. Conclusions This shows that reliable recommended mice because there good metabolite concentrations variation among doses, not confounder

Language: Английский

Citations

0
From rejection to recognition: Human rights, morality, and the future of Marijuana policy in Indonesia DOI
Aga Natalis,

Adventi Ferawati Sembiring,

Emy Handayani

et al.

International Journal of Drug Policy, Journal Year: 2025, Volume and Issue: 140, P. 104817 - 104817

Published: April 22, 2025

Language: Английский

Citations

0
Chemometrics‐Assisted Electrochemical Device for Cannabidiol Detection in Real Cannabis sativa Samples DOI Open Access

Wanda Cimmino,

Ada Raucci, Antonella Miglione

et al.

Chemistry - Methods, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

In recent years, the medical use of Cannabis sativa ( C. ), particularly cannabidiol (CBD), has gained significant attention. The expanding CBD market reflects growing consumer demand for natural remedies and wellness products. This study aimed to develop an electrochemical sensor quantifying in extracts using a homemade polyester screen‐printed electrode. sensor's performance was evaluated against liquid chromatography‐tandem mass spectrometry, achieving accuracy approximately 80%. A key challenge overlap between tetrahydrocannabinol (THC). To address this, novel quality control approach introduced principal component analysis. statistical method effectively distinguished samples based on cannabinoid content, revealing structural insights. platform exhibited limit detection 0.3 μg mL −1 quantification 1.15 , with strong reproducibility (relative standard deviation < 7%). successfully classified real Hashish, Marijuana, extracts, distinguishing CBD‐rich from THC‐dominant samples. underscores value integrating sensors techniques improve cannabis product assessment. Future research may extend this other cannabinoids terpenes, its potential industry.

Language: Английский

Citations

0